

T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, Massachusetts 02421

May 31, 2024

Via EDGAR

Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

Re: **T2 Biosystems, Inc.**
Registration Statement on Form S-3
Filed May 28, 2024
File No. 333-279740

To whom it may concern:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, T2 Biosystems, Inc. (the “***Company***”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-279740) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on June 4, 2024 or as soon as practicable thereafter.

The Company requests that we be notified of such effectiveness by a telephone call to N. Danny Shulman of Latham & Watkins LLP at (212) 906-4510 and that such effectiveness also be confirmed in writing.

Very truly yours,

T2 Biosystems, Inc.

By: /s/ John Sperzel
John Sperzel
President, Chief Executive Officer and Chairman of the
Board

cc: Evan Smith, Latham & Watkins LLP
Steven Stokdyk, Latham & Watkins LLP